Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Analytik Jena AG. (12/19/14). "Press Release: Analytik Jena Announces Group Figures for 2013/2014 Financial Year". Jena.

Organisations Organisation Analytik Jena AG
  Group Endress+Hauser (Group)
  Organisation 2 AJZ Engineering GmbH
  Group Endress+Hauser (Group)
Product Product analytical instrument
Person Person Berka, Klaus (Analytik Jena 200702 Chairman Executive Board)

> Operating business significantly below expectations despite sales increase of 24.2 %

> Extensive value adjustments due to the sharp decline of the Russian ruble lead to worst earnings in Company´s history

Analytik Jena AG (ISIN: DE0005213508, market segment: Prime Standard, Stock market symbol: AJA) closed the 2013/2014 financial year with Group revenue of EUR 121.3 m (previous year: EUR 97.7 m). Although this was 24.2 % more than in the previous year, the revenue increases resulted primarily from the project business of subsidiary AJZ Engineering, which was again fully consolidated and whose remaining shares (51.0 %) Analytik Jena AG reacquired on October 2, 2013 and in which it held 100.0 % in the reporting period. In the instrument business alone, total revenue amounted to EUR 99.7 m, nearly reaching the target in the annual forecast of EUR 100.0 m. Both the largest business unit Analytical Instrumentation and the Consumer Optics business with the DOCTER® brand, which is included in the Optics business unit, recorded revenue declines. The Life Science business unit could increase its revenue, but overall it was also not able to meet the expectations. Analytik Jena’s export ratio rose by 4.7 percentage points to 79.3 % (previous year: 74.6 %).

The Group concluded the financial year with earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR -1.3 m (previous year: EUR 6.8 m) with an EBITDA margin of -1.0 % (previous year: 6.9 %). EBIT amounted to EUR -6.2 m (previous year: EUR 2.1 m). Analytik Jena achieved an EBIT margin of -5.1 %, compared to 2.2 % in the previous year.

”While we could assert ourselves in the instrument business despite a number of negative influences, like unrest in the Arab countries or the Ukraine crisis, especially the sharp decline of the Russian ruble has led us to make value adjustments totalling almost EUR 7.0 m. At present we are continuing to observe a significant decline of the Ruble, that we have to expect further losses“, said Klaus Berka, CEO of Analytik Jena AG.

The extensive loss of earnings in the previous financial year is also attributable to the operating core business that was below expectations. Besides the weak operating business, the reporting period was influenced by some essential decisions in view of the future of the Company. This includes company foundations in important markets, the merger of the subsidiary CyBio AG to the Analytik Jena and the acquisition of the ICP-MS business of Bruker. Closely linked with that were increased expenses in sales, administration and R&D, that are reflected in the earnings. The operating profit was especially negatively effected by declining organic revenues in all three business units of the instrument business. „Operating profits in Life Science, in Optics and in Project Business were negative. Solely the business unit Analytical Instrumentation generated a still positive operating profit, although significantly below previous year. Due to investments into the future sales structures in Thailand, France and India the earnings situation was additionally effected“, Berka said.

At the end of the financial year, Analytik Jena recorded a consolidated net loss for the year of EUR -9.2 m (previous year: EUR -3.1 m). As of September 30, 2014, after deducting the results attributable to non-controlling interests, the Group reported a consolidated net loss for the year attributable to shareholders of the parent company of EUR -9.2 m (previous year: EUR -3.2 m). Including the results recorded directly in equity, the Group reported a total comprehensive income for the year of EUR -9.2 m (previous year: EUR -2.9 m). Both basic and diluted earnings per share amounted to EUR -1.21 (previous year: EUR -0.56).

”It is the worst result that the Company has ever achieved in its history. We have already taken numerous measures to at least stabilize our core business. We assume that Analytik Jena will clearly return to profit after a weak short financial year lying ahead of us“, Berka adds.

As of September 30, 2014, the Group had a total of 1,098 employees, including 35 interns (previous year: 983 employees, including 45 interns), or 11.7 % more than as of the previous balance sheet date. Personnel growth was essentially the result of increasing the number of shares of AJZ Engineering GmbH in October 2013 to 100.0 %. The expansion of the international sales network, such as the growth in the number of employees at the foreign companies in France, China, India, and Thailand, and the employees taken on as part of the acquisition of the ICP-MS business of the Bruker Corporation also affected the number of Group employees.

The complete financial report is available at

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Endress+Hauser (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top